Curaleaf Holdings has completed the acquisition of the remaining 45% stake it did not previously own in Four 20 Pharma GmbH, a German producer and distributor of fully EU-GMP and GDP licensed medical cannabis. Four 20 Pharma is recognized for its high quality cultivation, pharmaceutical grade processing and comprehensive distribution network in Germany and several European markets serving nursing homes, pharmacies and research institutions. The company’s commitment to compliance, patient care and scientific rigor positions it as a cornerstone of the European medical cannabis ecosystem.

The full acquisition of Four 20 Pharma vertically strengthens Curaleaf’s integrated global supply chain, from proprietary cultivation sources in Portugal and Canada to licensed distribution throughout Germany, providing patient quality assurance from seed and full oversight at every stage. Since the initial agreement in 2022, Curaleaf and Four 20 Pharma have worked closely together to expand patient access, advance research initiatives and streamline the international cannabis supply chain by validating a data-driven approach to education, cultivation and product development.

© Curaleaf

“Completing this acquisition of the remaining stake in Four 20 Pharma reinforces our commitment to Europe and the strategic importance of building high-quality local operations in a market that will continue to grow significantly,” said Boris Jordan, CEO and President of Curaleaf. “Four 20 Pharma’s leadership in production, fulfillment and distribution allows us to expand patient access to medical cannabis while driving innovation in the international market. This investment has been a significant and strategic anchor in our international strategy, and we look forward to continued long-term growth in Europe.”

“Joining Curaleaf as a fully integrated subsidiary marks an exciting new chapter for Four 20 Pharma,” said Torsten Greif, Founder and Managing Director of Four 20 Pharma. “We built this company on an uncompromising commitment to quality, compliance and patient care, values ​​that align perfectly with Curaleaf’s international mission. Together, we are positioned to set the standard for medical cannabis in regulated markets around the world.”

Building on the success of Four 20 Pharma in Germany, Curaleaf has already launched the Four 20 brand in the UK and Poland and plans to continue expanding the brand to additional international markets, leveraging the quality and fulfillment model that has made Four 20 Pharma one of Germany’s most trusted medical cannabis brands.